Table 5. Relationship between kinases and androgen receptor with clinical outcome measures.

	Time to biochemical relapse	Survival from biochemical relapse	Disease-specific survival
AR cytoplasm	0.466	0.922	0.517
AR nucleus	0.001	0.688	0.233
AR total	<0.001	0.711	0.580
pARS81 cytoplasm	0.166	0.578	0.057
pARS81 nucleus	0.594	0.407	0.031
pARS81 total	0.925	0.383	0.039
pARS94 cytoplasm	0.927	0.793	0.864
pARS94 nucleus	0.375	0.202	0.991
pARS94 total	0.178	0.425	0.884
pARS308 cytoplasm	0.255	0.423	0.423
pARS308 nucleus	0.974	0.634	0.628
pARS308 total	0.685	0.275	0.297
pARS515 cytoplasm	0.020	0.016	<0.001
pARS515 nucleus	0.877	0.189	0.072
pARS515 total	0.708	0.216	0.034
pARS650 cytoplasm	0.977	0.431	0.113
pARS650 nucleus	0.909	0.229	0.177
pARS650 total	0.530	0.342	0.059
Cdk1 cytoplasm	0.988	0.011	0.007
Cdk1 nucleus	0.791	0.624	0.434
Cdk1 total	0.827	0.337	0.134
pCdk1161 cytoplasm	0.396	0.356	0.013
pCdk1161 nucleus	0.889	0.026	0.001
pCdk1161 total	0.166	0.413	0.007
pERK1/2 cytoplasm	0.353	0.188	0.668
pERK1/2 nucleus	0.384	0.207	0.509
pERK1/2 total	0.525	0.487	0.973

Abbreviations: AR=androgen receptor; CC=Pearson’s correlation coefficients; PSA=prostate-specific antigen.

The proteins were grouped as ⩽median or >median and analysed by Kaplan–Meier methods with reference to clinical outcome measures as shown. Patients were considered to have biochemical relapse dependent on treatment; radical prostatectomy serum PSA >0.2 ng ml⁻¹, radical radiotherapy serum PSA of 2.0 ng ml⁻¹ above the post-treatment nadir level, hormone treatment 2–3 consecutive rises in serum PSA levels above the nadir obtained at intervals of >2 weeks (Roach et al, 2006; Cookson et al, 2007). Numbers in bold denote significant associations with P-value <0.05.